Glenmark Pharmaceuticals Limited has submitted to the Exchange, Unaudited Financial Results (Standalone and Consolidated) for the Second Quarter and Half Yearended 30th September, 2025.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has filed its unaudited financial results for the second quarter and first half of the financial year ending 30th September 2025 with the stock exchange. The filing covers both standalone and consolidated numbers. The actual financial figures are contained in the attached results document and not in the announcement text itself. This is a routine quarterly compliance filing under SEBI listing regulations.
No direct impact from this announcement alone — investors should review the detailed results document for revenue, profit, and margin trends to assess the company's quarterly performance.